Organigram Holdings Inc. is the parent company of Organigram Inc., which a licensed CBD producer. The company recently entered into an agreement with 1812 Hemp, an industrial hemp research company. The agreement says Organigram will provide a supply of CBD for the research and development of improving hemp by traditional breeding methods.
The agreement also allows for Organigram to receive access to a secure supply of hemp flower that has a high level of CBD, the active ingredient in hemp and cannabis. CBD is recognized for its therapeutic and other uses.
According to Greg Engel, Organigram’s CEO,
“Maximizing the CBD yield of hemp and cannabis means being able to meet increasing consumer demand for CBD while reducing overall production costs. We are proud to work with other industry-leading companies and researchers to continue to explore the potential of hemp and cannabis plants and the efficiency with which we can deliver CBD to our customers.”
This agreement comes in light of more CBD-friendly legislation that has spurred insight into agriculture technology, plant breeding, research, and development. 1812 Hemp is looking toward the future and is excited about providing considerable research capacity and insight into crop development and cultivation.
“We see the future CBD market in Canada and beyond to be an incredible opportunity” explains Engel. “CBD infused products will only grow in both medical and adult recreational channels, and we are focused on establishing the right relationships and processes now to fully take advantage of that opportunity.”
Organigram is able to access 6,000 kg of dried hemp flower and is planning on beginning the extraction process soon.